Clinica Oculistica Università di Genova, Genoa, Italy.
Am J Ophthalmol. 2012 Mar;153(3):474-480.e1. doi: 10.1016/j.ajo.2011.08.015. Epub 2011 Oct 22.
To determine the efficacy of half-dose photodynamic therapy (PDT) in relation to indocyanine green angiography (ICGA) and optical coherence tomography (OCT) findings for treating chronic central serous chorioretinopathy (CSC).
Observational case series.
Thirty-eight eyes of 37 patients with chronic CSC and symptoms for at least 6 months were recruited. PDT was performed using half the normal dose of verteporfin. A total light energy of 50 J/cm(2) over 83 seconds was delivered to the area of choroidal hyperfluorescence as observed on ICGA. The resolution of the subretinal fluid and recurrence rates were assessed in relation to the different degrees of choroidal hyperfluorescence and the distribution of fluid in the neuroepithelium, namely subretinal fluid or posterior retinal cystoid degeneration.
After half-dose PDT a dry macula was obtained in 86.8% and 92.1% of the eyes at 1 month and at the last follow-up (14.2 ± 5.8 months) respectively. ICGA at baseline showed intermediate and intense hyperfluorescence in 39.4% and 60.5% of the eyes respectively. All eyes with intermediate hyperfluorescence had only subretinal fluid at OCT and a dry macula was obtained in 87% and 100% at 1 month and at the last follow-up after half-dose PDT. In the intense hyperfluorescence group, 82.6% and 17.4% of the eyes had subretinal fluid only or both subretinal fluid and posterior retinal cystoid degeneration respectively. In the intense hyperfluorescence group with subretinal fluid only, a dry macula was obtained in 89.5% and 100% of the eyes at 1 month and at the last follow-up respectively. In the intense hyperfluorescence group with both subretinal fluid and posterior retinal cystoid degeneration, a dry macula was obtained in 75% and 25% of the eyes at 1 month and at the last follow-up respectively. Overall, of the 23 eyes with intense hyperfluorescence, 20 eyes (87%) had a dry macula starting from 1 month for the entire follow-up period.
The half-dose PDT success rate in eyes with chronic CSC depends also on the distribution of fluid in the neuroepithelium. Half-dose PDT might not be effective or the recurrence rate might be high in eyes with posterior retinal cystoid degeneration.
通过对比吲哚青绿血管造影(ICGA)和光相干断层扫描(OCT)结果,评估半剂量光动力疗法(PDT)治疗慢性中心性浆液性脉络膜视网膜病变(CSC)的疗效。
观察性病例系列。
招募了 37 名患者的 38 只患有慢性 CSC 且症状持续至少 6 个月的眼。采用维替泊芬的半剂量进行 PDT。在 ICGA 观察到脉络膜强荧光的区域,以 50 J/cm²的总光能量在 83 秒内传递。根据脉络膜强荧光的不同程度以及视网膜神经上皮内液体的分布(即视网膜下液或后部视网膜囊样变性),评估视网膜下液的消退和复发率。
半剂量 PDT 后 1 个月和末次随访(14.2 ± 5.8 个月)时,86.8%和 92.1%的眼获得干性黄斑。基线时 ICGA 显示,分别有 39.4%和 60.5%的眼有中等强度和高强度的强荧光。所有 OCT 显示仅存在视网膜下液的中等强度强荧光眼,半剂量 PDT 后 1 个月和末次随访时,分别有 87%和 100%的眼获得干性黄斑。在高强度强荧光组中,82.6%和 17.4%的眼分别仅有视网膜下液或同时存在视网膜下液和后部视网膜囊样变性。在仅有视网膜下液的高强度强荧光组中,半剂量 PDT 后 1 个月和末次随访时,分别有 89.5%和 100%的眼获得干性黄斑。在同时存在视网膜下液和后部视网膜囊样变性的高强度强荧光组中,半剂量 PDT 后 1 个月和末次随访时,分别有 75%和 25%的眼获得干性黄斑。总的来说,在 23 只高强度强荧光眼中,有 20 只(87%)眼从 1 个月开始,在整个随访期间均获得干性黄斑。
慢性 CSC 眼半剂量 PDT 的成功率也取决于视网膜神经上皮内液体的分布。对于后部视网膜囊样变性的眼,半剂量 PDT 可能无效或复发率较高。